Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of F61 injection in adults with mild/common COVID-19
ChiCTR2200066135Phase 2Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of F61 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoint: Time from baseline to continuous negative conversion of SARS-CoV-2 in swab samples. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
F61
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200066135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066135.